Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Delmer

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
Annals of Hematology|September 8, 2014
Rituximab therapy for hairy cell leukemia: a retrospective study of 41 casesMathieu Leclerc, Felipe Suarez, Marie-Pierre Noël, et al.
Blood|August 12, 2006
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) studyJehan Dupuis, Jean-François Emile, Nicolas Mounier, et al.
Virchows Archiv : an International Journal of Pathology|November 2, 2004
CD10 expression in diffuse large B-cell lymphomas does not influence survivalBettina Fabiani, Alain Delmer, Eric Lepage, et al.
American Journal of Hematology|May 3, 2016
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemiaLaetitia Souchet, Vincent Levy, Maya Ouzegdouh, et al.
American Journal of Hematology|November 23, 2017
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)Sophie Godet, Caroline Protin, Jehan Dupuis, et al.
Clinical Pharmacokinetics|October 27, 2016
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO GroupMira Tout, Anne-Laure Gagez, Stéphane Leprêtre, et al.
Oncotarget|January 7, 2017
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphomaClémentine Sarkozy, Sarah Huet, Victoria E H Carlton, et al.
American Journal of Hematology|September 30, 2014
Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patientsAnne Quinquenel, Chadi Al Nawakil, Fanny Baran-Marszak, et al.
Hemasphere|May 1, 2023
Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and RituximabCyrielle Rodier, Lukshe Kanagaratnam, David Morland, et al.
Annals of Hematology|April 3, 2009
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamideKarim Maloum, Catherine Settegrana, Elise Chapiro, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Annals of Hematology|September 8, 2014
Rituximab therapy for hairy cell leukemia: a retrospective study of 41 casesMathieu Leclerc, Felipe Suarez, Marie-Pierre Noël, et al.
Blood|August 12, 2006
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) studyJehan Dupuis, Jean-François Emile, Nicolas Mounier, et al.
Virchows Archiv : an International Journal of Pathology|November 2, 2004
CD10 expression in diffuse large B-cell lymphomas does not influence survivalBettina Fabiani, Alain Delmer, Eric Lepage, et al.
American Journal of Hematology|May 3, 2016
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemiaLaetitia Souchet, Vincent Levy, Maya Ouzegdouh, et al.
American Journal of Hematology|November 23, 2017
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)Sophie Godet, Caroline Protin, Jehan Dupuis, et al.
Clinical Pharmacokinetics|October 27, 2016
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO GroupMira Tout, Anne-Laure Gagez, Stéphane Leprêtre, et al.
Oncotarget|January 7, 2017
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphomaClémentine Sarkozy, Sarah Huet, Victoria E H Carlton, et al.
American Journal of Hematology|September 30, 2014
Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patientsAnne Quinquenel, Chadi Al Nawakil, Fanny Baran-Marszak, et al.
Hemasphere|May 1, 2023
Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and RituximabCyrielle Rodier, Lukshe Kanagaratnam, David Morland, et al.
Annals of Hematology|April 3, 2009
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamideKarim Maloum, Catherine Settegrana, Elise Chapiro, et al.
Pageof 11